MX2022001008A - Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. - Google Patents

Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.

Info

Publication number
MX2022001008A
MX2022001008A MX2022001008A MX2022001008A MX2022001008A MX 2022001008 A MX2022001008 A MX 2022001008A MX 2022001008 A MX2022001008 A MX 2022001008A MX 2022001008 A MX2022001008 A MX 2022001008A MX 2022001008 A MX2022001008 A MX 2022001008A
Authority
MX
Mexico
Prior art keywords
elevated levels
methods
cxcl9
biomarkers
compositions
Prior art date
Application number
MX2022001008A
Other languages
English (en)
Inventor
Walter Ferlin
Min Cristina De
Benedetti Fabrizio De
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of MX2022001008A publication Critical patent/MX2022001008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar la linfohistiocitosis hemofagocítica (HLH); la descripción también se refiere en general a métodos y composiciones para diagnosticar y tratar trastornos asociados con niveles elevados de CXCL9, niveles elevados de IFN? total y otros biomarcadores; la descripción también se refiere a métodos para tratar, retrasar la progresión de, o mejorar de otro modo, un síntoma de un trastorno en pacientes con niveles elevados de CXCL9, niveles elevados de IFN? total y otros biomarcadores que usan agentes que interfieren o antagonizan de otro modo con la señalización del interferón gamma (IFN?), incluida la neutralización de anticuerpos anti-IFN?.
MX2022001008A 2015-05-07 2017-11-07 Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. MX2022001008A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158153P 2015-05-07 2015-05-07
US201562221393P 2015-09-21 2015-09-21
US201562246949P 2015-10-27 2015-10-27

Publications (1)

Publication Number Publication Date
MX2022001008A true MX2022001008A (es) 2022-02-22

Family

ID=56008603

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014294A MX2017014294A (es) 2015-05-07 2016-05-09 Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
MX2022001008A MX2022001008A (es) 2015-05-07 2017-11-07 Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014294A MX2017014294A (es) 2015-05-07 2016-05-09 Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.

Country Status (13)

Country Link
US (2) US11034760B2 (es)
EP (1) EP3292147A1 (es)
JP (3) JP2018515493A (es)
KR (1) KR20180004254A (es)
CN (1) CN107849127A (es)
AU (1) AU2016257023B2 (es)
BR (1) BR112017023867A2 (es)
CA (1) CA2985001A1 (es)
EA (1) EA037532B1 (es)
IL (3) IL302519A (es)
MX (2) MX2017014294A (es)
SG (1) SG10202108996PA (es)
WO (1) WO2016177913A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202108996PA (en) * 2015-05-07 2021-09-29 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
BR112019008156A2 (pt) * 2016-10-24 2019-07-02 Novimmune Sa métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama
CN109164266B (zh) * 2017-11-27 2021-09-24 首都医科大学附属北京友谊医院 细胞因子在区分淋巴瘤相关噬血细胞综合征和淋巴瘤中的应用
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
EP3762416A4 (en) * 2018-03-09 2021-12-08 Children's Hospital Medical Center COMPOSITIONS AND METHODS OF TREATMENT OF MACROPHAGE ACTIVATION SYNDROME
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP7396213B2 (ja) 2020-06-22 2023-12-12 Tdk株式会社 データ解析システム、データ解析方法及びデータ解析プログラム
CN115812671A (zh) * 2022-11-17 2023-03-21 青岛大学 帕金森病动物模型的建立方法及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599306A (en) 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3887011B2 (ja) 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
AU2003231802A1 (en) 2002-05-17 2003-12-02 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1848744B1 (en) * 2005-01-27 2012-01-18 Novimmune SA Human anti-interferon gamma antibodies and methods of use thereof
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
KR102031020B1 (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
CN104159919A (zh) * 2011-11-23 2014-11-19 安姆根有限公司 使用抗干扰素γ抗体的治疗方法
US20170360929A1 (en) * 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
SG10202108996PA (en) 2015-05-07 2021-09-29 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Also Published As

Publication number Publication date
US11034760B2 (en) 2021-06-15
JP2018515493A (ja) 2018-06-14
IL282923B2 (en) 2023-10-01
JP2023090964A (ja) 2023-06-29
IL282923A (en) 2021-06-30
MX2017014294A (es) 2018-08-09
BR112017023867A2 (pt) 2018-07-24
AU2016257023B2 (en) 2022-06-30
AU2016257023A1 (en) 2017-11-30
IL255440B (en) 2021-08-31
WO2016177913A1 (en) 2016-11-10
EP3292147A1 (en) 2018-03-14
US20210101972A1 (en) 2021-04-08
IL255440A0 (en) 2017-12-31
EA037532B1 (ru) 2021-04-08
CA2985001A1 (en) 2016-11-10
CN107849127A (zh) 2018-03-27
IL302519A (en) 2023-07-01
JP2021100943A (ja) 2021-07-08
SG10202108996PA (en) 2021-09-29
US20160326244A1 (en) 2016-11-10
KR20180004254A (ko) 2018-01-10
IL282923B1 (en) 2023-06-01
EA201792447A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2022001008A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
PH12017502153A1 (en) Diagnostic methods for t cell therapy
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
NZ723884A (en) Methods of treating alzheimer’s disease
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX2016008516A (es) Metodos terapeuticos y composiciones.
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions
MX354598B (es) Uso de neuregulina para tratar lesion de nervio periferico.
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2020002462A (es) Estratificacion de genotipo en tratamiento y prevencion de diabetes.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2019000677A (es) Células miméticas de células b.